Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269395 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
A Phase 3 study, sponsored by Galderma R&D.
- Terminated
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT04269395: Clinical Trial Phase 3 study, sponsored by Galderma R&D.
NCT04269395 is a Phase 3 study that was terminated before completion, run by Galderma R&D. The registered enrollment target is 125 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04269395, a Phase 3 study, was terminated before completion, sponsored by Galderma R&D.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The primary purpose for this study is to assess recurrence of Actinic Keratosis in participants achieving complete response treated in earlier study.
Primary Outcome
Participants with recurrence are defined as the participants with recurrence of any (greater than and equal to \[\>=\] 1) cleared treated AK lesions. Number of participants with recurrence of any (\>=1) cleared treated AK lesions at Week 54 was reported.
Interventions
- DRUG Vehicle cream
- DRUG MAL Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 3 |
Why NCT04269395 stopped before completion
NCT04269395 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle cream is the first listed.
NCT04269395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04269395 about?
NCT04269395 is a clinical study titled "A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study". The primary purpose for this study is to assess recurrence of Actinic Keratosis in participants achieving complete response treated in earlier study.
What is the current status of trial NCT04269395?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2020-04-07. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT04269395?
The interventions under investigation include: Vehicle cream (DRUG), MAL Cream (DRUG).
Who is sponsoring clinical trial NCT04269395?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04269395's enrollment target sits among peer trials
125 1605th of 2000 higher than 391 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI